Trial may help millions of men suffering from enlarged prostate
Webster, TX – HTX Urology in Webster, TX (www.htxurology.com) is participating in an FDA-approved research study for a new, minimally invasive device pioneered by Urotronic, Inc., that could dramatically change the way millions of men with enlarged prostates are treated.
Urotronic’s Optilume® BPH Catheter System pairs innovative design with powerful drug therapy to provide a simple, anatomy-sparing procedure that doesn’t cut, burn, laser, steam or leave anything behind in the prostate like the other BPH technologies.
Dr. R. Robert Dhir from HTX Urology said he is “very excited” about the potential of this procedure. “This may be a promising solution for many of our patients,” Dr. Dhir said. “They will benefit tremendously from its convenience and the fact it’s minimally invasive. There’s no other treatment option like it out there right now.”
An enlarged prostate or Benign Prostatic Hyperplasia (BPH) affects nearly 40 million American men however only 12 million men are treated for BPH. Many men are unwilling to deal with the side effects of medical therapy or are reluctant to undergo an invasive surgical procedure. Consequently, millions of men are left to deal with the symptoms of BPH including frequent urination, increased frequency of urination at night, an urgent need to urinate, weak stream and straining to urinate.
Dr. Dhir is particularly optimistic about the Optilume BPH Catheter System following a prior clinical study in Latin America with 80 men who suffered from moderate-to-severe lower urinary tract symptoms secondary to BPH. The clinical study found that patient quality of life symptom scores improved on average by 60% or greater at three, six and 12 months.
Investigators will monitor the progress of the current clinical trial, which is now enrolling patients and following them for five years. The FDA will monitor the progress as well.
The Optilume BPH Catheter System is an investigational device, not available for sale. CAUTION- Investigational Device. Limited by Federal law to investigational use.
About Urotronic, Inc.
Urotronic, Inc., headquartered in Plymouth, Minnesota, is an early-stage medical device company currently conducting clinical trials to support global commercialization of its products. The Optilume drug-coated balloon technology provides a low-cost, minimally invasive treatment option for men suffering from urinary tract conditions like benign prostatic hyperplasia (BPH) and urethral strictures. The prevalence of BPH and lower urinary tract issues rises markedly with increased age. The drug-coated balloon technology under clinical investigation has the potential to become a paradigm change from the methods currently used by urologists to treat these conditions. For more information on Urotronic and its products, please visit www.urotronic.com.
If you’re interested in participating in this study, contact HTX Urology at 713-907-6054.
